Physician profile
Kylee Stouder
NPI 1093203226
$4,439.19
in general payments reported to CMS, 2019-2025
34 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $910 · 2022: $1,235 · 2023: $603 · 2024: $666 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $740.12 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $617.45 | 2021-2025 | Ubrelvy, Vraylar |
| Dexcom, INC. | $331.94 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $305.27 | 2021-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $295.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $235.67 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $195.96 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $182.26 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $172.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.79 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $130.25 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $122.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $100.20 | 2022 | |
| Astellas Pharma US INC | $90.77 | 2022-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $88.83 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $82.80 | 2021-2022 | |
| Pfizer INC. | $80.43 | 2022-2025 | |
| Eisai INC. | $65.99 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $64.63 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $52.51 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $48.16 | 2022-2025 | Capvaxive, Gardasil 9 |
| Radius Health, INC. | $35.79 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $33.11 | 2021-2022 | |
| Irhythm Technologies, INC. | $32.37 | 2023 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $31.96 | 2021 | |
| Abiomed | $30.76 | 2025 | |
| Inspire Medical Systems, INC. | $22.92 | 2024 | Inspire |
| Ibsa Pharma INC. | $22.53 | 2025 | Tirosint, Flector, Licart |
| Dynavax Technologies Corporation | $19.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.34 | 2023 | Quviviq |
| Clarus Therapeutics INC. | $14.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.99 | 2022 | |
| Acerus Pharmaceuticals Corporation | $13.72 | 2022 | |
| Ironshore Pharmaceuticals INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylee Stouder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.